ADVANCED CANCER
Clinical trials for ADVANCED CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED CANCER trials appear
Sign up with your email to follow new studies for ADVANCED CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug DS-9606a tested in early trial, but stopped early
Disease control TerminatedThis early-phase study tested an experimental drug called DS-9606a in 88 people with advanced solid tumors that have a specific protein (Claudin-6). The main goal was to check safety and find the right dose. The trial was terminated, meaning it stopped before completion, so we ha…
Matched conditions: ADVANCED CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new antibody drug (BGB-B3227) alone or with another drug (tislelizumab) in 35 people with advanced solid tumors. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: ADVANCED CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New cancer drug tested in people with advanced tumors
Disease control TerminatedThis early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…
Matched conditions: ADVANCED CANCER
Phase: PHASE1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Cancer combo trial halted early: what went wrong?
Disease control TerminatedThis early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the …
Matched conditions: ADVANCED CANCER
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 17:56 UTC